DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for paraplegia — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleParaplegia maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for paraplegia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
spastin (SPAST) — SPAST is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet adpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6PEK · 4.2 Å · ligand ADENOSINE-5'-DIPHOSPHATE (ADP). Experimental structure, not a prediction.
What the evidence adds up to
Hereditary spastic paraplegia is a genetically transmitted disease, usually autosomal dominant, characterised by slow progression of spastic paraparesis. In one series of six families with 26 affected members, all initial referrals were children with slowly progressive paraplegia, slightly delayed motor milestones, normal intellect, and no history of perinatal cerebral event. The condition is frequently misdiagnosed as cerebral palsy. In Caucasian populations, heterozygous Spastin mutations account for the majority of patients (SPG4), with predominant clinical manifestation within the third or fourth decade of life. Clinical manifestation during childhood is well known but more common in less frequent forms such as SPG3a or complicated HSP, for example SPG11.
Acute paraplegia is an emergency requiring immediate assessment to rule out compressive lesions of the cord. Early intervention may preserve neurological spinal function and limit persistent disability. Acute paraplegia may also be complicated by life-threatening problems requiring prompt recognition and treatment. For hereditary spastic paraplegia, the pathogenesis is complex, and there is no effective method to prevent it or postpone the occurrence and progress of the disease. Gene detection is the gold standard for diagnosis.
Therapeutic strategies, following a correct diagnosis, have to be addressed to improving the patient's quality of life by rehabilitation methods and medication targeting the pathophysiological processes involved. In the 1988 series, each child was treated when necessary with appropriate tendon lengthenings. Recognition is the key to management; a careful patient and family history reveals the hereditary nature and helps develop treatment plans.
What is still missing is any proven disease-modifying therapy for hereditary spastic paraplegia, as no drug is mentioned in these abstracts that alters the course of the disease. There is no randomised trial data, no patient stratification beyond genetic subtyping, and no funding directed at a specific pharmacological intervention. The evidence base remains limited to diagnosis, rehabilitation, and symptomatic management.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Pediatric Orthopaedics · 1988 · 11 citations
Hereditary Spastic Paraplegia
AbstractHereditary spastic paraplegia is a genetically transmitted disease that is usually autosomal dominant. Characterized by a slow progression of spastic paraparesis, it is frequently misdiagnosed as cerebral palsy. Our experience consists of six families with a total of 26 affected members. All initial referrals were children with a slowly progressive paraplegia. Each child was noted to have slightly delayed motor milestones, normal intellect, and no history of perinatal cerebral event. Each child was treated when necessary with appropriate tendon lengthenings. Recognition is the key to management. A careful patient and family history will reveal the hereditary nature of the disease and help develop treatment plans.
The Patient with Acute Paraplegia: A Problem-Based Review
AbstractAcute paraplegia is an emergency requiring immediate assessment by the acute medical team because of the need to rule out compressive lesions of the cord. Early intervention may preserve neurological spinal function and limit persistent disability. In addition, acute paraplegia may be complicated by life-threatening problems. These require prompt recognition and treatment. The following clinical scenario, based on a real case of acute paraplegia managed by the authors is aimed at providing a problem-based approach to the management of patients presenting with acute paraplegic weakness.
Mutation Spectrum and Infantile Manifestation in Hereditary Spastic Paraplegia
AbstractAims: Hereditary spastic paraplegia (HSP) is genetically heterogeneous and clinically characterized by gait impairment because of weakness and spasticity of the lower limbs. In Caucasian populations, heterozygous Spastin mutations account for the majority of patients (SPG4) with predominant clinical manifestation within the third or fourth decade of life. A clinical manifestation during childhood is well known, but more common in less frequent forms such as SPG3a or complicated HSP, for example, SPG11.
Balneo Research Journal · 2019 · 0 citations · open access
Pallidopyramidal Syndrome and Hereditary Spastic Paraplegia common features and diagnostic approach and therapeutic considerations
AbstractThe neurological diagnosis, can be, in some situations, a challenging one. Clinical presentation for neurological disease, which has no imagistic diagnosis criteria, can develop during several month or years. Therefore, the first evaluation of the patient with neurological symptoms is not always conclusive. Pallidopyramidal syndrome and hereditary spastic paraplegia (HSP) can present common features and diagnostic approach has to be careful. genetic assessment is the gold diagnosis method in some cases. Therapeutic strategies, following a correct diagnosis has to be addressed to improvement the patient's quality of life by rehabilitation methods and medication targeting the pathophysiological processes involvement. The aim of this paper is to discuss the clinical evolution and the diagnosis strategies in hereditary spastic paraplegia.
Progress in diagnosis of hereditary spastic paraplegia
AbstractHereditary spastic paraplegia is a rare group of neurodegenerative diseases with high clinical and genetic heterogeneity. Its pathogenesis is complex, and the clinical manifestations are slow progressive weakness of the lower limbs and spastic paraplegia. With the progress of the disease, there is no effective method to prevent it or postpone the occurrence and progress of the disease. The incidence of this disease is low, and gene detection is the gold standard for diagnosis.
Key words:
Hereditary spastic paraplegia; Gene diagnosis; Differential diagnosis
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
